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ABNORMAL CARBOHYDRATE METABOLISM IN BRONCHOGENIC CARCINOMA*
E. F. VALDES, M.D., Chief of Medical Department, N. S. ROMEO, M.D., Chief of Medical Service, AND D. L.
PERAZZO, M.D., Chief of Section, Faculty of Medicine, University of Buenos Aires, Argentina
Recently hyper- and hypometabolic states have been
described that are related to various neoplasms.'" The
first report came from Freund, in 1885: concerning
hyperglycaemia in 62 out of 70 patients with neoplasms.
His findings were confirmed by Tuffier," and Rebitzer'
described patients in whom the cancer had preceded the
appearance of the diabetes.
By means of the glucose-tolerance test Theis and StoneS
studied 180 patients with carcinomas and found positive
results in 26%. Langston9 obtained similar results. He
stated that there did not seem to be a typical or charac-
teristic curve in cases with carcinoma and suggested that
the abnormal carbohydrate metabolism was the result of
the overgrowth of tumour cells.
Puchulu et al.' studied a group of 324 neoplasms of
diverse origin and found overt diabetes in 14'2% of the
cases; in 127 cases of bronchogenic carcinomas they
found 17·5% with overt diabetes. They suggest that
bronchogenic cancer acts as a precipitating factor of a
genetically determined diabetes.
We studied a group of 35 patients with certified
histopathology who had not received specific treatment,
and matched them by age and sex with a control group
of 35 healthy subjects by means of a modified Conn and
Fajans test.
MATERIALS AND METHODS
Two groups of 35 patients of comparable sex and age
were studied by means of a modified Conn and Fajans
test (by venepuncture). The group with bronchogenic
carcinoma comprised 32 males and 3 females, with ages
ranging from 45 to 78 years. The control group of nor-
mal persons ranged from 49 to 76 years (32 males and 3
females).
Patients for the first group had to fulfil the following
criteria:
(a) Histopathologically confirmed bronchogenic car-
cinoma (by means of endoscopic and! or lymph node
biopsy) had to be present.
(b) Only patients who had not received any specific
treatment (surgical, radiotherapy or chemotherapy)
were included.
'Date received: 3 December 1968.
(c) They had to be without overt diabetes, liver di-
sease, infection or fever.
Technique
The glucose-tolerance test was performed in the fol-
lowing way: a diet of 1,800 - 2,300 calories, containing
300 G of carbohydrates, was administered for 3 days be-
fore the test. At 8 p.m. on the evening before the test 10
mg. of prednisone was administered, and a further 10 mg.
at 6 a.m. on the morning of the test. Blood samples were
obtained immediately before and at 60, 120 and 180
minutes after the intravenous administration of 100 G
of anhydrate glucose solution. Determinations of blood
sugar were made by the method of Folin and Wu.
In the statistical analysis each point of the curve was
considered and was regarded as abnormal when the dif-
ference was more than 2 standard deviations of the
normal mean.
RESULTS AND DISCUSSION
The results obtained revealed significant differences in the
incidence of abnormal GTT between the group of
bronchogenic carcinomas and the control group. The per-
centage incidence of abnormal GTT was 43'9.% in the
carcinomatous patients and 22'6% in the controls (Fig. 1).
There was a direct relationship between the incidence
of latent diabetes and the grade of differentiation of the
tumour.
According to the histopathology, 50% of the squamous
carcinomas, 32% of the adenocarcinomas and 18 % of the
oat-cell carcinomas presented abnormalities in the carbo-
hydrate metabolism (Fig. 2). Such a finding is difficult to
explain in the light of present knowledge, and several
mechanisms such as enzymatic, hormonal or immunologi-
cal have been postulated (Table I).
Glicksman' suggests that the cancer would increase the
plasma level of the glucolytic enzymes (phosphohexose-iso-
merase and others). He found 41 % abnormal tests in 39
patients with bronchogenic carcinomas, and only 10% in
benign tumours of the lung.
Another physiopathogenic possibility is the production
of hormonal-like diabetogenic substances by the tumour
tissue, and the abnormal carbohydrate metaboli.im could
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be the reflection of overstimulation of the adrenal gland.
We have recently found greater concentrations of 17-
hydroxycorticoids in the urine of patients with broncho-
genic carcinoma.'· and abnormal carbohydrate metabolism.
Recently Hecker et al." demonstrated sustained hyper-
glycaemja during a glucose-galactose tolerance test in
patients with lung carcinoma while they were studying
the lactose absorption.
It has also been postulated' that the tumour produces
an insulin-antagonistic substance specifically affecting the
peripheral action of this hormone.
or-
Hyperactivity ofces gluco-
tion lytic enzymes (pho pho-
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TABLE I. DIABETOGE le FACTOR INCRI '11 ATED IN THE
BRONCHOGENIC CA CER
Investigations should be continued in order to clarify
the mechanism by which diabetes IS 0 commonly
associated with bronchogenic carcinomas and to obtain
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Fig. J. Incidence of diabetogenic curves in patients with






Studies have been conducted to evaluate carbohydrate meta-
bolism in 2 groups of 35 patients of comparable age and sex.
One group consisted of patients with bronchogenic carcinoma
(free of treatment), while the normal subjects formed the con-
trol group. .
The results revealed an incidence of abnormal GlT In
43·9~0 of the cases of bronchogenic cancer, a against 22·6"" in
the control group.
According to the histopathology of neoplasms the abnormal
glucose-tolerance tests were more frequent in the epitheliallype
(50 0 0 ) than in the adenocarcinoma (32~o) or the undifferentiated
type (18~0).
The pathogenic mechanism of this change i not known, but
it is suggested that the tumour produces insulin-antagoni tic
substances of a hormonal-like diabetogenic ubstance.
Fig. 2. Bio-histopathological correlation between broncho-
genic carcinoma with diabetogenic test and the hi to-








Recent studies have shown tbat the GTT returned to norm,,1
after surgical (2 cases) and radiotherapeutic (I case) treatment
of carcinomas.
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